MIDATECH PHARMA
News | News Release
Jun 13, 2017
R&D manufacturing site visit for investors and analysts

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, is hosting a site visit today at its state-of-the-art manufacturing site in Bilbao, Spain for institutional investors and sell-side analysts.

The site visit will be hosted by Jim Phillips, CEO and will include presentations from Craig Cook, CMO, as well as a talk from the perspective of a patient diagnosed with DIPG (diffuse intrinsic pontine glioma) and treated with Midatech’s lead R&D programme, MTX110.

Programme updates will include:

  • Q-Octreotide (MTD201) for carcinoid syndrome and acromegaly, which is on track to start its first in human equivalence study later this year versus Novartis’ market leading Sandostatin LAR product
  • Childhood brain cancer program (MTX110), which is now rapidly moving towards a Phase I/II study in the US and/or EU/UK, and following the license deal with Novartis, announced last week
  • Liver cancer programme (MTD119), which continues to show encouraging efficacy results in pre-clinical models.  The latest orthotopic liver cancer study is underway and is already showing higher anti-tumour effects compared to the current standard of care, sorafenib
  • Also included will be an update on the adult brain cancer glioblastoma MTR103 program, as well as the Group’s pioneering research in cancer immuno-therapy and the developing supportive scientific rationale for using the Group’s gold nano-particle technology for cancer immuno-therapy

Attendees will be given a tour of the GMP manufacturing facilities: the first plant licensed in Europe for nanoparticle manufacture, which was recently upgraded to enable the manufacture of sustained release products under clean conditions.

No new price sensitive information will be disclosed at the event and presentations will be available on Midatech’s website on 14th June 2017.

News
News Release
Jun 13, 2017
R&D manufacturing site visit for investors and analysts

Midatech Pharma (AIM: MTPH; Nasdaq: MTP), the international specialty pharmaceutical company focused on commercialising and developing products in oncology, is hosting a site visit today at its state-of-the-art manufacturing site in Bilbao, Spain for institutional investors and sell-side analysts.

The site visit will be hosted by Jim Phillips, CEO and will include presentations from Craig Cook, CMO, as well as a talk from the perspective of a patient diagnosed with DIPG (diffuse intrinsic pontine glioma) and treated with Midatech’s lead R&D programme, MTX110.

Programme updates will include:

  • Q-Octreotide (MTD201) for carcinoid syndrome and acromegaly, which is on track to start its first in human equivalence study later this year versus Novartis’ market leading Sandostatin LAR product
  • Childhood brain cancer program (MTX110), which is now rapidly moving towards a Phase I/II study in the US and/or EU/UK, and following the license deal with Novartis, announced last week
  • Liver cancer programme (MTD119), which continues to show encouraging efficacy results in pre-clinical models.  The latest orthotopic liver cancer study is underway and is already showing higher anti-tumour effects compared to the current standard of care, sorafenib
  • Also included will be an update on the adult brain cancer glioblastoma MTR103 program, as well as the Group’s pioneering research in cancer immuno-therapy and the developing supportive scientific rationale for using the Group’s gold nano-particle technology for cancer immuno-therapy

Attendees will be given a tour of the GMP manufacturing facilities: the first plant licensed in Europe for nanoparticle manufacture, which was recently upgraded to enable the manufacture of sustained release products under clean conditions.

No new price sensitive information will be disclosed at the event and presentations will be available on Midatech’s website on 14th June 2017.

© Copyright 2017 Midatech Pharma PLC